Intranigral dopamine toxicity and α-synuclein response in rats

Neurochemical Research

Volumn 31, Issue 7, 2006, Pages 861-868

  Gómez Santos, Cristina ^a   Giménez Xavier, Pol ^b   Ferrer, Isidre ^b   Ambrosio, Santiago ^b  

^a Centro Nacional de Investigación de Enfermedades Neurológicas Bellvitge   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Synuclein; Apoptosis; Dopamine; Neurodegenerative diseases; Substantia nigra

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANESTHESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; BRAIN DAMAGE; BRAIN NERVE CELL; CELL DAMAGE; CELL LOSS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; CYTOPLASM; DEGENERATIVE DISEASE; DIMERIZATION; DOPAMINERGIC NERVE CELL; ENDOPLASMIC RETICULUM; HISTOLOGY; MALE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; RAT; RISK ASSESSMENT; STRESS; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANIMALS; BLOTTING, WESTERN; CELL-FREE SYSTEM; DOPAMINE; MALE; MICROSCOPY, ELECTRON; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

EID: 33746486176     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-006-9090-2     Document Type: Article

References (45)

1. Barzilai A, Melamed E, Shirvan A (2001) Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease? Cell Mol Neurobiol 21:215-235
2. Barzilai A, Daily D, Zilkha-Falb R, Ziv I, Offen D, Melamed E, Shirvan A (2003) The molecular mechanisms of dopamine toxicity. Adv Neurol 91:73-82
3. Offen D, Ziv I, Panel H, Wasserman L, Stein R, Melamed E, Barzilai A (1997) Dopamine-induced apoptosis is inhibited in PC12 expressing bcl-2. Cell Mol Neurobiol 17:289-304
4. Lai C-T, Yu PH (1997) Dopamine- and 1-β-3,4-dihydroxyphenylalanine hydrochloride (l-dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Biochem Pharmacol 53:363-372
5. Michel PP, Hefti F (1990) Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 25:428-435
6. McLaughlin BA, Nelson D, Erecinska M, Chesselet MF (1998) Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by mitochondrial inhibitors. J Neurochem 70:2406-2415
7. Filloux F, Townsend J (1993) Pre- and post-synaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol 119:79-88
8. Hattori A, Luo Y, Umegaki H, Munoz J, Roth GS (1998) Intrastriatal injection of dopamine results in DNA damage and apoptosis in rats. Neuroreport 9:2569-2572
9. Ungerstedt U (1976) 6-Hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. Pharmacol Ther 2:37-40
10. Slivka A, Cohen G (1985) Hydroxyl radical attack on dopamine. J Biol Chem 260:15466-15472
11. Sulzer D, Bogulavsky J, Larsen KE, Behr GE, Karatekin E, Kleinman MH, Turro N, Krantz D, Edwards RH, Greene LA, Zecca L (2000) Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci USA 97:11869-11874
12. Simantov R, Blinder E, Ratovitski T, Tauber M, Gabbay M, Porat S (1996) Dopamine-induced apoptosis in human neuronal cell: inhibition by nucleic acids antisense to the dopamine transported. Neuroscience 74:39-50
13. Gómez-Santos C, Ferrer I, Santidrián AF, Barrachina M, Gil J, Ambrosio S (2003) Dopamine induces autophagic cell death and α-synuclein increase in human neuroblastoma SH-SY5Y cells. J Neurosci Res 73:341-350
14. Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Márquez J, Mouatt-Prigent A, Ruberg M, Hirsch EC, Agid Y (1997) Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 12:25-31
15. Stokes AH, Freeman WM, Mitchell SG, Burnette TA, Hellmann GM, Vrana KE (2002) Induction of GADD45 and GADD153 in neuroblastoma cells by dopamine-induced toxicity. Neurotoxicol 23:675-684
16. Holtz WA, O'Malley KL (2003) Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J Biol Chem 278:19367-19377
17. Oyadomari S, Mori M (2004) Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 11:381-389
18. Gómez-Santos C, Barrachina M, Giménez-Xavier P, Dalfó E, Ferrer I, Ambrosio S (2005) Induction of C/EBPβ and GADD153 expression by dopamine in human neuroblastoma cells; relationship with α-synuclein increase and cell damage. Brain Res Bull 65:87-95
19. Bennett MC (2005) The role of α-synuclein in neurodegenerative diseases. Pharmacol Ther 103:311-331
20. Vila M, Przedborski S (2004) Genetic clues to the pathogenesis of Parkinson's disease. Nature Med 10 Suppl:S58-S62
21. Espino A, Llorens J, Calopa M, Bartrons R, Rodriguez-Farré E, Ambrosio S (1995) Cerebrospinal dopamine metabolites in rats after intrastriatal administration of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium ion. Brain Res 669:19-25
22. Kearns CM, Gash DM (1995) GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 672:104-111
23. Schmued LC, Albertson C, Slikker A Jr (1997) Fluoro-jade: a novel fluorochrome for the sensitive reliable histochemical localization of neuronal degeneration. Brain Res 751:37-46
24. Aroca P, Solano F, García-Borrón JC, Lozano JA (1990) A new spectrophotometric assay for dopachrome tautomerase. J Biochem Biophys Methods 21:35-46
25. Ariano MA, Grissell AE, Littlejohn FC, Buchanan TM, Elsworth JD, Collier TJ, Steece-Collier K (2005) Partial dopamine loss enhances activated caspase-3 activity: differential outcomes in striatal projection systems. J Neurosci Res 82:387-396
26. Altar CA, Marien M, Marshall JF (1987) Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury. J Neurochem 48:390-399
27. Zuch CL, Nordstroem VK, Briedrick LA, Hoering GR, Granholm AC, Bickford PC (2000) Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion. J Comp Neurol 427: 440-454
28. Kopin IJ (1993) Neurotransmitters and disorders of the basal ganglia. In: Siegel GJ, Agranoff BW, Albers RW, Molinoff PB (eds). Basic Neurochemistry. Raven Press, New York, p 93
29. Baker AJ, Zornow MH, Scheller MS, Yaksh TL, Skilling SR, Smullin DH, Larson AA, Kuczenski R (1991) Changes in extracellular concentrations of glutamate, aspartate, glycine, dopamine, serotonin, and dopamine metabolites after transient global ischemia in the rabbit brain. J Neurochem 57:1370-1379
30. Gómez C, Ferrer I, Reiriz J, Viñals F, Barrachina M, Ambrosio S (2001) Low concentrations of 1-methyl-4-phenylpyridinium ion induce caspase-mediated apoptosis in human SH-SY5Y neuroblastoma cells. Brain Res 935:32-39
31. Liang Q, Liou AK, Ding Y, Cao G, Xiao X, Perez RG, Chen J (2004) 6-Hydroxydopamine induces dopaminergic cell degeneration caspase-9-mediated apoptotic pathway that is attenuated by caspase-9dn expression. J Neurosci Res 77:747-761
32. Junn E, Mouradian MM (2001) Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases. J Neurochem 78:374-383
33. Cutillas B, Espejo M, Gil J., Ferrer I, Ambrosio S (1999) Caspase inhibition protects nigral neurons against 6-hydroxydopamine-induced retrograde degeneration. Neuroreport 10:2605-2608
34. Conn KJ, Gao W-W, Ullman MD, McKeon-O'Malley C, Eisenhauer PB, Fine RE, Wells JM (2002) Specific upregulation of GADD153/CHOP in 1-methyl-4-phenyl- pyridinium-treated SH-SY5Y cells. J Neurosci Res 68:755-760
35. Giménez-Xavier P, Gómez-Santos C, Castaño E, Francisco R, Boada J, Unzeta M, Sanz E, Ambrosio S (2006) The decrease of NAD(P)H has a prominent role in dopamine toxicity. Biochim Biophys Acta 1762:564-574
36. Harrington KA, Augood SJ, Kingsbury AE, Foster OJF, Emson PC (1996) Dopamine transported (DAT) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease. Mol Brain Res 36:157-162
37. Fahn S (1997) Levodopa-induced neurotoxicity, does it represent a problem for the treatment of Parkinson's disease? CNS Drugs 8:376-393
38. Bustamante D, You Z-B, Castel M-N, Johansson S, Goiny M, Terenius L, Hökfelt T, Herrera-Marschitz M (2002) Effect of single and repeated methamphetamine treatment on neurotransmitter release in substantia nigra and neostriatum of the rat. J Neurochem 83:645-654
39. Sidhu A, Wersinger C, Moussa CEH, Vernier P (2004) The role of α-synuclein in both neuroprotection and neurodegeneration. Ann N Y Acad Sci 1035:250-270
40. Vila M, Vukasovic S, Jackson LV, Neystat M, Jakowec M, Przedborski S (2000) α-Synuclein up-regulation in substantia nigra of dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 74:721-729
41. Conway KA, Rochet JC, Bieganski RM, Landsbury PT (2001) Kinetic stabilization of the α-synuclein protofibril by a dopamine-α- synuclein adduct. Science 294:1346-1349
42. Souza JM, Giasson BI, Chen Q, Lee VM Y, Ischiropoulos H (1999) Dityrosine cross-linking promotes formation of stable α-synuclein polymers. J Biol Chem 275:18344-18349
43. Krishnan S, Chi EY, Wood SJ, Kendrick BS, Li C, Garzón- Rodríguez W, Wypych J, Randolph TW, Narhi L-O, Biere AL, Citron M, Carpenter JF (2003) Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease α-synuclein fibrillogenesis. Biochemistry 42:829-837
44. Linert W, Jameson GNL (2000) Redox reactions of neurotransmitters possibly involved in the progression of Parkinson's disease. J Inorg Biochem 79:319-326
45. Norris EH, Giasson BI, Hodara R, Xu S, Trojanowski JQ, Ischiropoulos H, Lee VM (2005) Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J Biol Chem 280:21212-21219